Neurocrine Biosciences
NBIX
NBIX
330 hedge funds and large institutions have $6.44B invested in Neurocrine Biosciences in 2018 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 110 increasing their positions, 111 reducing their positions, and 89 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% less funds holding
Funds holding: 345 → 330 (-15)
16% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 89
41% less capital invested
Capital invested by funds: $10.9B → $6.44B (-$4.46B)
Holders
330
Holding in Top 10
7
Calls
$82.5M
Puts
$53.6M
Top Buyers
| 1 | +$233M | |
| 2 | +$117M | |
| 3 | +$106M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$44.8M |
| 5 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$35.4M |
Top Sellers
| 1 | -$134M | |
| 2 | -$79.2M | |
| 3 | -$77M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$54M |
| 5 |
Goldman Sachs
New York
|
-$52.3M |